Initial Steroid Treatment in a MOGAD Patient with Super High MOG Antibody and Lesion without Contrast Enhancement

Files

Authors

Ayla Barakat, Corewell Health West Resident
Ling Ling Rong, Corewell Health West
Nicholas Lannen, Corewell Health West
Jessica Feistel, Corewell Health West

Description

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a central nervous system autoimmune demyelinating disease, distinct from multiple sclerosis and neuromyelitis optic spectrum disorder radiologically and histopathologically, also in treatment response and outcomes. The presence of MOG-IgG is the core criterion for diagnosing MOGAD. Whether extremely high MOG-antibody titers affect treatment response has not been elucidated. Here we report a case of a patient with extremely high MOG-IgG level and non-enhancing lesion in the spinal cord, who demonstrated rapid response to steroid therapy.

Publication Date

5-9-2025

Disciplines

Neurology

Recommended Citation

Barakat A, Lannen N, Ling Ling Rong MD; Jessica Feistel MD. Initial steroid treatment in a MOGAD patient with super high MOG antibody and lesion without contrast enhancement. Presented at: Research Day Corewell Health West; 2025 May 9; Grand Rapids, MI.

Comments

2025 Research Day Corewell Health West, Grand Rapids, MI, May 9, 2025. Abstract 1691